America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -447.29 Thousand USD | 90.54% |
| 2022 | -4.72 Million USD | -1798.77% |
| 2021 | -249.01 Thousand USD | -439.55% |
| 2020 | -46.15 Thousand USD | 3.32% |
| 2019 | - USD | 17.91% |
| 2018 | - USD | -20.23% |
| 2017 | - USD | 95.76% |
| 2016 | -1.14 Million USD | -72.89% |
| 2015 | -660.09 Thousand USD | 0.0% |
| 2014 | - USD | 100.0% |
| 2013 | -107.37 Thousand USD | -90.85% |
| 2012 | -56.26 Thousand USD | -155.45% |
| 2011 | -22.02 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -150.16 Thousand USD | -110.81% |
| 2024 Q3 | -130.56 Thousand USD | 13.06% |
| 2024 Q1 | -71.23 Thousand USD | 53.71% |
| 2023 Q4 | -153.87 Thousand USD | -42.44% |
| 2023 FY | - USD | 90.54% |
| 2023 Q1 | -126.73 Thousand USD | 94.05% |
| 2023 Q2 | -58.64 Thousand USD | 53.73% |
| 2023 Q3 | -108.03 Thousand USD | -84.21% |
| 2022 Q2 | -1.75 Million USD | -488.34% |
| 2022 FY | - USD | -1798.77% |
| 2022 Q4 | -2.12 Million USD | -284.0% |
| 2022 Q3 | -554.24 Thousand USD | 68.39% |
| 2022 Q1 | -298.03 Thousand USD | -102.26% |
| 2021 Q3 | -13.41 Million USD | -38627.57% |
| 2021 Q4 | 13.2 Million USD | 198.41% |
| 2021 FY | - USD | -439.55% |
| 2021 Q1 | -1182.00 USD | 96.37% |
| 2021 Q2 | -34.63 Thousand USD | -2830.54% |
| 2020 FY | - USD | 3.32% |
| 2020 Q4 | -32.53 Thousand USD | -2095.01% |
| 2020 Q3 | -1482.00 USD | 85.16% |
| 2020 Q2 | -9986.00 USD | -363.82% |
| 2020 Q1 | -2153.00 USD | 90.55% |
| 2019 Q4 | -22.78 Thousand USD | -202.59% |
| 2019 Q3 | -7531.00 USD | 39.83% |
| 2019 FY | - USD | 17.91% |
| 2019 Q1 | -4902.00 USD | 76.74% |
| 2019 Q2 | -12.51 Thousand USD | -155.32% |
| 2018 Q2 | -15.07 Thousand USD | -16.81% |
| 2018 FY | - USD | -20.23% |
| 2018 Q4 | -21.07 Thousand USD | -131.57% |
| 2018 Q3 | -9099.00 USD | 39.64% |
| 2018 Q1 | -12.9 Thousand USD | 73.32% |
| 2017 Q2 | -860.69 Thousand USD | -1913.61% |
| 2017 Q1 | -42.74 Thousand USD | 19.31% |
| 2017 Q3 | 12.12 Thousand USD | 101.41% |
| 2017 Q4 | -48.36 Thousand USD | -498.93% |
| 2017 FY | - USD | 95.76% |
| 2016 Q2 | -130.06 Thousand USD | 80.97% |
| 2016 Q3 | -274.79 Thousand USD | -111.27% |
| 2016 Q1 | -683.38 Thousand USD | -273.64% |
| 2016 Q4 | -52.97 Thousand USD | 80.72% |
| 2016 FY | - USD | -72.89% |
| 2015 Q2 | -159.62 Thousand USD | -0.52% |
| 2015 Q4 | -182.9 Thousand USD | -15.19% |
| 2015 Q3 | -158.78 Thousand USD | 0.53% |
| 2015 Q1 | -158.79 Thousand USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q3 | -151.69 Thousand USD | -204.05% |
| 2014 Q1 | -20.49 Thousand USD | 67.54% |
| 2014 Q4 | - USD | 100.0% |
| 2014 FY | - USD | 100.0% |
| 2014 Q2 | -49.89 Thousand USD | -143.49% |
| 2013 Q2 | -18.19 Thousand USD | -50.39% |
| 2013 Q4 | -63.11 Thousand USD | -367.72% |
| 2013 Q3 | -13.49 Thousand USD | 25.82% |
| 2013 Q1 | -12.09 Thousand USD | 75.39% |
| 2013 FY | - USD | -90.85% |
| 2012 Q2 | -2684.00 USD | -140.07% |
| 2012 Q3 | -4417.00 USD | -64.57% |
| 2012 Q1 | -1118.00 USD | 39.53% |
| 2012 Q4 | -49.16 Thousand USD | -1012.97% |
| 2012 FY | - USD | -155.45% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | -1849.00 USD | -496.45% |
| 2011 Q3 | -310.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 98.484% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 99.608% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 97.162% |
| Better Therapeutics, Inc. | -38.26 Million USD | 98.831% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 98.831% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 97.499% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 98.674% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 98.66% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 99.579% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | 51.034% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 98.623% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 99.042% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 92.13% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 97.256% |
| Molecular Templates, Inc. | 1.43 Million USD | 131.279% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 96.776% |
| NexImmune, Inc. | -28.16 Million USD | 98.412% |
| Orgenesis Inc. | -60.71 Million USD | 99.263% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 99.128% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -509.257% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 97.23% |
| Scopus BioPharma Inc. | -11.71 Million USD | 96.181% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 99.917% |
| Statera Biopharma, Inc. | 38.93 Million USD | 101.149% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 93.502% |
| Trevena, Inc. | -35.28 Million USD | 98.732% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -698.009% |
| Vaccinex, Inc. | -19.74 Million USD | 97.735% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 57.278% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 99.046% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 93.842% |